Revolution Medicines (RVMD) Competitors

$147.30 +2.93 (+2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$147.15 -0.16 (-0.11%)

As of 07:58 PM Eastern

RVMD vs. SNY, GSK, TAK, ARGX, and TEVA

Should you buy Revolution Medicines stock or one of its competitors? MarketBeat compares Revolution Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revolution Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Revolution Medicines compare to Sanofi?

Revolution Medicines (NASDAQ:RVMD) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Sanofi has a net margin of 16.95% compared to Revolution Medicines' net margin of 0.00%. Sanofi's return on equity of 13.39% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Sanofi	16.95%	13.39%	7.58%

Revolution Medicines currently has a consensus price target of $108.88, suggesting a potential downside of 26.09%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 17.11%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A
Sanofi	$49.35B	2.15	$8.84B	$3.58	12.16

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Revolution Medicines had 2 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Revolution Medicines and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.67 beat Revolution Medicines' score of 0.53 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to GSK?

Revolution Medicines (NASDAQ:RVMD) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 3 more articles in the media than GSK. MarketBeat recorded 6 mentions for Revolution Medicines and 3 mentions for GSK. Revolution Medicines' average media sentiment score of 0.53 beat GSK's score of 0.23 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GSK has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A
GSK	$43.07B	2.41	$7.54B	$3.85	13.26

Revolution Medicines presently has a consensus target price of $108.88, suggesting a potential downside of 26.09%. GSK has a consensus target price of $53.00, suggesting a potential upside of 3.82%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

GSK has a net margin of 17.82% compared to Revolution Medicines' net margin of 0.00%. GSK's return on equity of 44.28% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
GSK	17.82%	44.28%	11.49%

Revolution Medicines has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, GSK has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

GSK beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Takeda Pharmaceutical?

Revolution Medicines (NASDAQ:RVMD) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Takeda Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.53

Revolution Medicines presently has a consensus target price of $108.88, indicating a potential downside of 26.09%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Takeda Pharmaceutical had 10 more articles in the media than Revolution Medicines. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 6 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.53 beat Takeda Pharmaceutical's score of 0.06 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to Revolution Medicines' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 11.07% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Summary

Revolution Medicines beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

argenex (NASDAQ:ARGX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

60.3% of argenex shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 8.2% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 1 more articles in the media than argenex. MarketBeat recorded 6 mentions for Revolution Medicines and 5 mentions for argenex. argenex's average media sentiment score of 0.72 beat Revolution Medicines' score of 0.53 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

argenex presently has a consensus target price of $1,017.78, suggesting a potential upside of 27.58%. Revolution Medicines has a consensus target price of $108.88, suggesting a potential downside of 26.09%. Given argenex's higher probable upside, analysts plainly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

argenex has a net margin of 31.31% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 33.28% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Revolution Medicines	N/A	-83.22%	-59.06%

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.62	$1.29B	$22.46	35.52
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A

Summary

argenex beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Revolution Medicines	N/A	-83.22%	-59.06%

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.65
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, indicating a potential upside of 22.44%. Revolution Medicines has a consensus price target of $108.88, indicating a potential downside of 26.09%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 6 mentions for Revolution Medicines. Teva Pharmaceutical Industries' average media sentiment score of 0.63 beat Revolution Medicines' score of 0.53 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.32B	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-20.83	18.70	20.58	25.09
Price / Sales	2,704.32	278.20	577.42	91.07
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	17.45	6.57	9.68	6.60
Net Income	-$1.13B	$24.30M	$3.55B	$335.71M
7 Day Performance	1.08%	-3.56%	-2.07%	-2.03%
1 Month Performance	-0.89%	-7.86%	-3.90%	-1.90%
1 Year Performance	268.90%	51.80%	29.39%	27.36%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	2.2785 of 5 stars	$147.30 +2.0%	$108.88 -26.1%	+265.1%	$30.69B	$11.58M	N/A	250	Analyst Forecast
SNY Sanofi	4.3215 of 5 stars	$42.50 -1.9%	$51.00 +20.0%	-15.8%	$105.63B	$47.35B	11.87	74,846
GSK GSK	3.2568 of 5 stars	$49.82 -1.2%	$53.00 +6.4%	+33.6%	$102.29B	$43.07B	12.95	66,841	Dividend Cut
TAK Takeda Pharmaceutical	2.0361 of 5 stars	$16.34 -0.8%	N/A	+17.5%	$52.38B	$30.09B	68.07	47,455	Analyst Downgrade
ARGX argenex	4.6501 of 5 stars	$813.28 +4.0%	$1,017.78 +25.1%	+37.2%	$48.64B	$4.25B	36.21	1,863

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. SNY, GSK, TAK, ARGX, and TEVA

How does Revolution Medicines compare to Sanofi?

Summary

How does Revolution Medicines compare to GSK?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. SNY, GSK, TAK, ARGX, and TEVA

How does Revolution Medicines compare to Sanofi?

Which has more risk & volatility, RVMD or SNY?

Is RVMD or SNY more profitable?

Do analysts prefer RVMD or SNY?

Which has higher earnings & valuation, RVMD or SNY?

Do institutionals & insiders hold more shares of RVMD or SNY?

Does the media refer more to RVMD or SNY?

Summary

How does Revolution Medicines compare to GSK?

Do institutionals and insiders believe in RVMD or GSK?

Does the media refer more to RVMD or GSK?

Which has preferable valuation & earnings, RVMD or GSK?

Do analysts prefer RVMD or GSK?

Is RVMD or GSK more profitable?

Which has more volatility & risk, RVMD or GSK?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Which has stronger valuation and earnings, RVMD or TAK?

Do analysts recommend RVMD or TAK?

Does the media favor RVMD or TAK?

Which has more risk and volatility, RVMD or TAK?

Do institutionals & insiders have more ownership in RVMD or TAK?

Is RVMD or TAK more profitable?

Summary

How does Revolution Medicines compare to argenex?

Do insiders and institutionals hold more shares of ARGX or RVMD?

Does the media prefer ARGX or RVMD?

Do analysts recommend ARGX or RVMD?

Which has more risk & volatility, ARGX or RVMD?

Is ARGX or RVMD more profitable?

Which has stronger earnings and valuation, ARGX or RVMD?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Which has more risk and volatility, TEVA or RVMD?

Is TEVA or RVMD more profitable?

Which has higher valuation & earnings, TEVA or RVMD?

Do analysts recommend TEVA or RVMD?

Do insiders & institutionals believe in TEVA or RVMD?

Does the media favor TEVA or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools